Transferrin receptor 1 mRNA is downregulated in placenta of hepcidin transgenic embryos  by Martin, Marie Elise et al.
FEBS 28751 FEBS Letters 574 (2004) 187–191Transferrin receptor 1 mRNA is downregulated in placenta
of hepcidin transgenic embryosMarie Elise Martina, Ga€el Nicolasa, Gilles Heteta, Sophie Vaulontb,
Bernard Grandchampa, Carole Beaumonta,*
aINSERM U409, Faculte de Medecine X. Bichat, Institut Federatif de Recherche 02, 16 rue Henri Huchard, 75018 Paris, France
bDepartement de Genetique, Developpement et Pathologie Moleculaire, Institut Cochin, Faculte de Medecine Cochin-Port Royal,
24 rue du Faubourg ST Jacques, 75014 Paris, France
Received 8 June 2004; revised 12 July 2004; accepted 3 August 2004
Available online 18 August 2004
Edited by Lukas HuberAbstract We have previously shown that hepcidin transgenic
embryos are severely anemic and die around birth. Here, we
report that embryonic hepcidin transgene expression decreases
transferrin receptor 1 (TfR1) mRNA level in placenta, as shown
by cDNA microarray analysis and quantitative RT-PCR, by a
mechanism which is independent of placenta iron content and
iron responsive element/iron regulatory protein (IRE/IRP)
activity. On the contrary, iron injections into pregnant mothers
result in increased placenta iron and ferritin content, and reduced
IRE binding activity of IRP1 leading to decreased TfR1 mRNA
level. Taken together, these results suggest that hepcidin action
on placenta is mostly through transcriptional downregulation of
the iron uptake machinery.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Compelling evidence suggests that hepcidin, a small cys-
teine-rich peptide synthesized by the liver and secreted in se-
rum, is a major regulator of iron homeostasis. Hepcidin
deﬁcient mice develop progressive iron overload of the pa-
renchyma, with paradoxical iron depletion in tissue macro-
phages [1] and patients with homozygous hepcidin mutations
develop a juvenile form of hemochromatosis [2]. Hepcidin is
also a key mediator of the anemia of chronic disease [3]. Based
on these observations, it has been proposed that hepcidin is the
‘‘store regulator’’, controlling intestinal iron absorption and
iron recycling by macrophages [3].
Its role in the control of the materno-fetal iron transfer at
the placenta level is not known but some of us have previously
reported that forced expression of hepcidin during develop-
ment in transgenic embryos leads to severe anemia and death
around birth, whereas the control littermates are perfectly
normal [4]. However, in these experiments, some transgenic* Corresponding author. Fax: +33-1-42264624.
Abbreviations: TfR1, transferrin receptor 1; IRE, iron responsive
element; IRP, iron regulatory protein; Gapdh, glyceraldehyde-3-
phosphate dehydrogenase; p.c., post-co€ıtum
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doi:10.1016/j.febslet.2004.08.010embryos were viable without iron therapy and it was therefore
possible to establish a transgenic mouse line (Thep27) consti-
tutively expressing hepcidin [5].
These results suggest that hepcidin produced by the embryo
can also block iron transfer from the mother to the foetus. Iron
transfer across the placenta requires iron uptake at the brush
border membranes by internalization of the maternal iron-
transferrin complex by placenta transferrin receptors [6], re-
lease of iron in the endosomes and transfer to the cytoplasm,
presumably by Nramp2/DMT1 [7], iron eﬄux at the baso-
lateral membrane of the syncytiotrophoblast through the
Fe(II) iron transporter ferroportin [8], also known as MTP1 [9]
or IREG1 [10] and subsequent oxidation by a membrane-
bound ceruloplasmin, which seems to be diﬀerent from the
duodenal hephaestin [11]. Placenta transferrin receptor 1
(TfR1) mRNA and protein have been shown to be both up-
regulated by iron deﬁciency in the mother [12]. This compen-
satory mechanism probably results from a relative iron
deﬁciency in the placenta, which stabilizes the TfR1 mRNA
through the iron responsive element/iron regulatory protein
(IRE/IRP) system. When cellular iron content is low, IRPs
remain in their native form and bind with high aﬃnity to IREs
located in the 30 untranslated region of the TfR1 mRNA,
thereby protecting it from degradation by endonucleases (for
review, see [13]).
The molecular targets of hepcidin remain mostly unknown.
To better understand the mechanism underlying the onset of
anemia in hepcidin transgenic embryos, we analyzed placenta
mRNA by cDNA microarrays dedicated to genes of iron
metabolism and anti-oxidant defenses and explored placenta
iron metabolism. The eﬀect of acute iron loading of the mother
on placenta iron metabolism was also analyzed.2. Materials and methods
2.1. Animals
Thepc27 hepcidin transgenic males of mixed C57BL/6x129/
SVxDBA/2 genetic background and three month old C57BL/6 female
mice were maintained under normal housing conditions. To induce
parenteral iron loading, three subcutaneous injections of 100 ll of an
iron-saccharose preparation (Venofer, Vifor International, Saint
Gallen, Switzerland) containing 2 mg elemental iron were performed in
the pregnant mothers on three consecutive days, 72, 48 and 24 h prior
to sacriﬁce.blished by Elsevier B.V. All rights reserved.
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The same method was used to extract RNA for cDNA microarray
analysis and for quantitative RT-PCR. Total RNA was isolated from
pieces of liver or placenta using the RNA Plus Extraction Solution kit
(Quantum Biotechnologies, Illkirch, France).
2.3. cDNA microarray analysis
We designed a custom oligonucleotide-based microarray for a se-
lection of genes involved in iron metabolism and antioxidant-defenses.
The corresponding list of genes and GenBank accession numbers, to-
gether with the conditions used for labeling, hybridization and scan-
ning of the data are available on our web site http://
www.bichat.inserm.fr/equipes/u409/suppl_art_MARTIN.htm.
2.4. Quantitative RT-PCR
Single-stranded cDNA was synthesized using SuperScriptTM Rnase
H Reverse Transcriptase (Invitrogen). Real-time quantiﬁcation of
transcripts was performed in 25 ll in ABI PRISM 7700 Sequence
Detector (PE Applied Biosystems, Courtaboeuf, France) using
SYBR Green PCR master mix (PE Applied Biosystems), 5 pmol of
forward and reverse primers and 2.5 ll of reverse transcriptase reaction
mixture. Sequences of the primers were as follows :
Tfr1 (69 bp), 50-GAGGAACCAGACCGTTATGTTGT-30 (for-
ward) and
50-CTTCGCCGCAACACCAG-30 (reverse);
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh; 177 bp), 50-
TGCACCACCAACTGCTTAG-30 (forward) and
50-GAATGCAGGGATGATGTTC-30 (reverse).
The result was normalized arbitrary on the sample with the lowest
CT value for Gapdh (named CT-Gapdh R). For all others samples, the
relative quantiﬁcation was calculated using comparative CT method
with the following arithmetic formula:
ð1þ EGapdhÞðCT-Gapdh RCT-Gapdh SÞ=ð1þ EXÞðCT-X RCT-X SÞ, where EGapdh is
the eﬃciency of Gapdh target ampliﬁcation and EX the eﬃciency of
ampliﬁcation for the gene of interest. CT-Gapdh R and CT-X R are the
respective threshold cycles for Gapdh and for the gene of interest of the
reference sample; CT-Gapdh S and CT-X S are the respective threshold
cycles for Gapdh and for the gene of interest of every sample but the
reference sample. The ampliﬁcation eﬃciency of each target was de-
termined using serial 2-fold dilutions of cDNA.
2.5. Tissue homogenization
Mice tissues were collected, weighted, minced, and dissolved in 10 ml
of lysis buﬀer (20 mM Tris–HCl, pH 7.4, 1 mM Na azide, 1 mM
PMSF, 10 lM leupeptin, 1 lM pepstatin, and 1 mM benzamidine) per
gram of wet tissue. Potter or sonication was used to disrupt the cells.
Debris were precipitated by centrifugation at 10 000 rpm for 10 min.
All the steps were performed at +4 C. Supernatants were used to
determine ferritin contents, or to analyze IRE/IRP interactions in some
cases. Protein concentration was determined in triplicate using the
BioRad protein assay and BSA as standard.
2.6. Quantiﬁcation of tissue non-heme iron and L ferritin content
Quantiﬁcation of iron levels was performed as described by Torrence
and Bothwell [14] on tissue samples by using an IL test (Instrumen-
tation Laboratory, Lexington, MA) on an Olympus AU400 automat.
L ferritin in tissue extracts was measured on the same automat, using
the Olympus human ferritin assay kit. Calibration curves obtained
with the human ferritin standard included in the kit and with re-
combinant mouse L ferritin (kindly provided by Dr. Paolo Santam-
brogio, Milano, Italy) showed almost perfect overlap.2.7. RNA gel shift assays of IRP activity
Mouse tissue extracts were prepared as described above and diluted
at 1 lg/ll in lysis buﬀer before use. IRE/IRP interactions were mea-
sured as previously described [15], by incubating a [32P]-labeled IRE-
HFt mRNA probe (3 · 104 cpm at 104 cpm/ng) transcribed in vitro
from pIL2CAT with 5 lg of cytoplasmic extracts. After 15 min. in-
cubation at room temperature, 5 mg/ml heparin was added for another
10 min. IRE-protein complexes were run on a 6% non-denaturing
polyacrylamide gel. In parallel experiments, extracts were treated with
2% b-mercaptoethanol for 10 min. prior to the addition of the IRE
probe to allow full expression of IRE binding activity. The radioac-
tivity associated with the IRE/IRP complexes was quantiﬁed with an
Instant Imager (Packard Instruments, Rungis, France).2.8. Statistical analysis
Statistical signiﬁcance was evaluated using the non-parametric
Mann Whitney test (unpaired, two-tailed) for comparison between two
medians. Correlation was performed by linear regression. GraphPad
Prism software (GraphPad Software, San Diego, CA) was used for
statistical evaluation.3. Results
3.1. Hepcidin induces TfR1 mRNA downregulation in placenta
To analyze the eﬀect of embryonic hepcidin expression on
placenta iron metabolism, we crossed transgenic Thepc27 males
constitutively expressing hepcidin with C57BL/6 wild type fe-
males. Hepcidin transgenic and non-transgenic embryos from
the same littermate and their respective placenta were isolated
at day 16.5 post co€ıtum, at a stage where endogenous embryonic
hepcidin is not normally expressed. As previously reported, the
transgenic embryos were very pale as compared to their non-
transgenic littermates [4]. To identify changes in gene expression
that might be induced in the placenta by the hepcidin produced
by the embryonic liver, we developed 50-mer oligonucleotide-
based cDNA microarrays dedicated to mouse iron genes.
PooledRNAs from two placenta of transgenic and two placenta
of non-transgenic embryos were labeled with Cy3 and Cy5,
respectively, and co-hybridized in duplicate on the mouse
dedicated cDNA microarrays. A second hybridization experi-
ment was performed with the reverse labeling. Most of the
studied genes including both ferritin subunits, Nramp2, ferro-
portin, and Dcytb had a clearly detectable expression in pla-
centa (>5 times the background signal) but did not show any
change in their expression. Only transferrin receptor mRNA
displayed a reduced expression (2.5-fold) in placenta from
transgenic embryos. These results were conﬁrmed by quanti-
tative RT-PCR. At 16.5, 17.5 and 18.5 days p.c., there was a 3-
to 5-fold reduction in TfR1 mRNA in placenta of transgenic
embryos as compared to those from non-transgenic embryos
(Fig. 1). These results were highly signiﬁcant (P < 0:005). TfR1
mRNA stability is known to be regulated by intracellular iron
through the IRE/IRP system. Our results suggest that sustained
hepcidin expression by the embryo induces iron accumulation
in the placenta, inactivation of IRE binding activity of the IRPs
and destabilization of TfR1 mRNA. To test this hypothesis, we
measured iron content in the placenta of transgenic and non-
transgenic embryo but found no diﬀerence between the two
conditions (Fig. 2A), although there was a moderate but sta-
tistically signiﬁcant increase in placenta L ferritin content
(Fig. 2B). Evaluation of the IRE binding activity of the IRPs by
gel retardation assay (Fig. 2C) showed that on an average, 60–
70% of IRP1 is in the apo form possessing an IRE binding ac-
tivity, both in control and in hepcidin transgenic placenta
(Fig. 2D). No IRP2 binding activity was detected, as previously
observed in mouse tissues [15] or human placenta [16]. Since
there is no change in placenta iron content and no modiﬁcation
in the IRE binding activity of the IRP, it is likely that the strong
reduction in TfR1 mRNA results from transcriptional repres-
sion of the TfR1 gene, rather than from degradation of TfR1
mRNA.
3.2. Acute iron overload in the mother does not induce iron
overload of the embryo
To determine to what extent placenta iron loading was ca-
pable of regulating TfR1 mRNA expression and IRP activity,
Fig. 2. Hepcidin transgene expression in embryonic liver does not
change IRP activity in the placenta. One litter from a mating with a
Thepc27 male was analyzed for each of the three stages of develop-
ment. Each litter consisted in three to ﬁve non-transgenic (black bars)
or three to ﬁve transgenic (open bars) embryos. Results are
meansS.D. of data obtained with all the placenta from the same
genotype. (A) Placenta non-heme iron. (B) Placenta L ferritin content,
determined with an Olympus automat. (C) IRE binding activity of the
IRP was evaluated by gel retardation assay using an IRE probe. An
autoradiogram of a typical gel shift experiments is shown, with the
IRE/IRP complex found in two non-transgenic (NTg) and two
transgenic (Tg) embryos at 18.5 days of development, in the presence
or absence of 2% bME. (D) Quantiﬁcations of the bands by Instant
Imager, expressed as percent of the total IRE binding activity in the
placenta from non-transgenic and transgenic embryos.
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Fig. 1. Hepcidin transgene expression in embryonic liver downregu-
lates TfR1 mRNA in the placenta. Quantitative RT-PCR experiments
were performed for placenta TfR1 mRNAs and normalized to Gapdh
mRNA. Placentas from non-transgenic (black bars) and from trans-
genic (open bars) embryos were analyzed. At each stage of develop-
ment, results are means±S.D. of data obtained for between 5 and 7
embryos of the same genotype resulting from two diﬀerent matings
between a wild type C57BL/6 mother with a Thepc27 hepcidin trans-
genic male. Diﬀerences between controls and transgenic TfR1 mRNA
levels were highly signiﬁcant (P < 0:005).
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wild type males and the consequences on placenta iron me-
tabolism were followed. Iron was injected to pregnant mothers
on three consecutive days prior to sacriﬁce at 17.5 day p.c. Iron
injections in pregnant mothers induced roughly a 10-fold iron
overload in their liver, although the total iron in the embryowas not modiﬁed. In the placenta, there was a 5-fold increase
in iron load (Fig. 3A), a moderate but statistically signiﬁcant
(P < 0:05) reduction in TfR1 mRNA expression (Fig. 3B), and
a 2-fold increase in L ferritin content (Fig. 3C). Iron accu-
mulation in the placenta reduced the IRE-binding activity of
IRP1, with only 30–35% of the IRP remaining in the apo form
in placenta from iron-overloaded mother (Fig. 3D and E).
These results suggest that transfer of iron from the placenta to
the embryo is a rate-limiting step and that iron accumulation
in the placenta subsequently downregulates TfR1 mRNA ex-
pression through inactivation of the IRP. Correlation between
IRP binding activity and TfR1 mRNA in the placenta of
embryos from both control and iron overloaded mothers
suggests that placenta iron content regulates TfR1 mRNA
levels through the IRE/IRP system (Fig. 3F).4. Discussion
In this paper, we demonstrate that hepcidin constitutively
produced by embryonic liver during development reduces
transferrin receptor mRNA in the placenta. This is the ﬁrst
description of a molecular eﬀect that can only be ascribed to
changes in native hepcidin expression. So far, all the evidence
we have that hepcidin is a major regulator of iron homeostasis
relies mostly on two lines of evidence. One is the observation
that hepcidin gene expression is upregulated by iron and LPS
[17,18] and downregulated by iron deﬁciency [19], phlebotomy,
or hypoxia [20]. The other one is brought about by the phe-
notype of animal models with modiﬁed hepcidin expression [1]
or by the identiﬁcation of hepcidin mutations in patients with
juvenile hemochromatosis [2]. Hepcidin is thought to down-
regulate intestinal iron absorption by duodenal enterocytes
and iron recycling by macrophages. The current view is that
hepcidin interacts with some components of the iron export
machinery [21], although the precise mechanism of these eﬀects
remains completely unknown. Our results suggest that long
term adaptation of the placenta to sustained embryonic hep-
cidin expression is through reduction of the iron uptake pro-
tein at the maternal side, although we cannot rule out the
possibility that hepcidin also downregulates iron eﬄux from
the placenta. This is in keeping with a recent publication
showing that intraperitoneal injection of synthetic hepcidin in
mice decreases duodenal iron uptake, as shown by tied oﬀ loop
experiments [22].
It is likely that this TfR1 mRNA reduction results from
transcriptional downregulation of the gene rather than reduced
stability of the mRNA, since placenta iron was not increased
by embryonic expression of hepcidin, and the IRE binding
activity of the IRP1 was not modiﬁed. On the contrary, ex-
perimental placenta iron overload inactivated the IRE binding
activity of the IRP1, increased ferritin synthesis and reduced
TfR1 mRNA accumulation, as expected. The strong correla-
tion between TfR1 mRNA and IRP1 activity in placenta from
both control and iron loaded mothers highlights the impor-
tance of the iron-mediated post-transcriptional regulations in
the control of the iron exchanges between the mother and the
foetus. The results obtained following acute iron loading of the
mother extend previous observations that in rats, iron deﬁ-
ciency in the mother results in activation of TfR1 mRNA ex-
pression [17] and that in humans, placentas from diabetic
Fig. 3. Placenta iron overload reduces IRP binding activity. Placentas from control mothers (black bars) or from two iron overloaded mothers
(hatched bars) were analyzed. (A) Non-heme iron was measured on six placentas for each condition. (B) TfR1 mRNA was measured by quantitative
RT-PCR and normalized to Gapdh mRNA, on six placentas for each condition. (C) Placenta L ferritin contents were determined with an Olympus
automat. Results are means S.D. of placentas ferritin measurement from 12 placentas from two litters for each condition. (D) IRE binding activity
of the IRP was evaluated by gel retardation assay using an IRE probe. An autoradiogram of a typical gel shift experiment is shown, with the IRE/
IRP complex found in two control and two iron-loaded placentas. (E) Quantiﬁcation of the bands by Instant Imager, expressed as percent of the total
IRE binding activity evaluated following exposure to 2% bME, is shown for six placentas from one control and six placentas from one overloaded
mother. (F) Correlation between IRE binding activity and TfR1 mRNA level for each placenta was made by linear regression.
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increased IRE binding activity of IRP1 [16]. The moderate
increase in L ferritin synthesis in transgenic placenta is diﬃcult
to explain, considering that the RNA-binding activity of IRP1
is not modiﬁed. However, decreased stability of IRP2, which
could not be evaluated in our experimental conditions, could
account for this eﬀect. IRP2 has been shown to dominate iron-
mediated post-transcriptional regulations in certain tissues
[23].
Transcriptional regulation of TfR1 gene expression has not
been studied in great details but it is known to be upregulated
when resting cells are induced to proliferate [24] or during
erythroid diﬀerentiation [25]. In addition, a functional HIF-1a
binding site located about 90 nucleotides upstream of the
transcription start site can mediate transcriptional activation
of the TfR1 gene in hypoxic conditions [26]. Interestingly, iron
is a key factor in the regulation of HIF-1a stability [27] and
cellular iron depletion can stabilize HIF-1a, even in normoxic
conditions [28]. Therefore, in some conditions, transcriptionalregulations of TfR1 gene expression can override the regula-
tion of mRNA stability by the IRP/IRE complexes, as it is
probably the case in response to embryonic hepcidin.
Finally, it will be important to establish whether hepcidin
action on one of its natural target organ such as the duodenum
also involves downregulation of proteins involved in iron up-
take like the iron reductase Dcytb or the iron transporter
Nramp2/DMT1.
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